From ZoomRx, trusted by 19 of the top 20 pharma firms

AI Agents for BD&L Workflows

Search and evaluate targets, pull deal comps, model peak sales, score PTRS, and run rNPV. Delivered as finished work, not raw search results.

Book a Demo
Efruxifermin - Opportunity Screening
Exec Summary Data Analytics Reports Alerts

Efruxifermin - Opportunity Screening

Akero Therapeutics · Phase IIb · MASH (Fc-FGF21)

Score: 87/100
Implied Value $5.2B Novo bid (2025)
Market Cap $3.7B Pre-deal (Akero)
Peak Sales $1.5B+ Peak sales est.
Phase IIb HARMONY trial
Mechanism FGF21 Fc-fusion analog

Investment Thesis

Efruxifermin is a long-acting Fc-FGF21 fusion protein with best-in-class Phase IIb HARMONY data in MASH: 41% fibrosis improvement (≥1 stage) vs. 20% placebo (p=0.036) at 50mg. 96-week Lancet data shows sustained and increasing anti-fibrotic response. FGF21 class validated by multiple large deals in 2025: Roche/89bio $3.5B, GSK/Boston Pharma $2B. MASH market projected to reach $31.8B by 2033 (CAGR 17.7%, DataM Intelligence).

Key Catalysts

1

Phase III SYNCHRONY trial initiation

Pivotal histological endpoints (FDA-aligned)

2

96-week HARMONY data published (Lancet)

Sustained anti-fibrotic response confirmed

3

Novo Nordisk acquisition closed ($5.2B)

Validates FGF21 class at premium

MASH Market Forecast ($B)
$7.9B CAGR $31.8B
2024 2027 2030 2033

Comparable MASH Deals

Deal
Type
Upfront
Total
Year
Novo / Akero (EFX)
Acq.
-
$5.2B
2025
Roche / 89bio (pego.)
Acq.
-
$3.5B
2025
GSK / Boston Pharma
Acq.
$1.2B
$2.0B
2025
Novo / Ventus (NLRP3)
License
$70M
$700M
2022
BI / Ochre Bio (RNA)
Collab.
$35M
>$1B
2024

Key Risks

Competitive crowding: Rezdiffra (approved Mar 2024) and semaglutide (approved Aug 2025) already on market. Survodutide has Breakthrough Therapy designation in Phase III.

FDA endpoint bar rising: OCA (Intercept) received CRL in June 2023 despite Breakthrough Therapy designation. Confirmatory outcomes trials now required (Rezdiffra MAESTRO-NASH ongoing).

Chat

How does efruxifermin compare to pegozafermin on fibrosis?

2:14 PM

HARMONY (24-wk): 39-41% fibrosis improvement vs 20% placebo. ENLIVEN (24-wk): 27% vs 7% placebo. Both FGF21 analogs. Note: cross-trial comparison only - different patient populations, not head-to-head.

2:14 PM

Why did Novo pay $5.2B vs Roche paying $3.5B for 89bio?

2:15 PM

Key factors: efruxifermin has stronger fibrosis data (39-41% vs 27%), 96-week durability published in Lancet, and strategic fit with Novo's GLP-1 MASH franchise (semaglutide). Combination potential with semaglutide adds premium.

2:15 PM